Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18 to 50 years (for the first 2 arms)~* Healthy adolescents (aged 12-14) for the third arm of the study~* Screening Elispot negative (less than 17 spots/million PBMC) in all 3 ESAT6 pools and all 3 CFP10 pools~* Mantoux test \<15mm (\<10mm if BCG naïve)~* CXR normal with no evidence of active or past TB~* For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day of vaccination~* Agreement to refrain from blood donation during the course of the study~* Written informed consent~* Willingness to undergo an HIV test~Exclusion Criteria:~* Any deviation from the normal range in biochemistry or haematology blood tests or in urine analysis as defined in Appendix I~* Mantoux \>15mm~* Prior receipt of a recombinant MVA or Fowlpox vaccine~* Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period~* Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune modifying drugs within six months of vaccination. (For corticosteroids, this will mean prednisolone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products~* Evidence of cardiovascular disease~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)~* History of diabetes mellitus~* Chronic or active neurological disease requiring ongoing specialist or medical supervision~* Chronic gastrointestinal disease requiring ongoing specialist or medical supervision~* History of \> 2 hospitalisations for invasive bacterial infections (pneumonia, meningitis)~* Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week~* Seropositive for hepatitis B surface antigen (HBsAg)~* Seropositive for hepatitis C virus (antibodies to HCV)~* Evidence of serious psychiatric condition~* Any other on-going chronic illness requiring hospital specialist or medical supervision~* Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate~* Pregnant or lactating female~* Female who is willing or intends to become pregnant during the study~* Any history of anaphylaxis in reaction to vaccination~* Inability to give informed consent~* PI assessment of lack of willingness to participate and comply with all requirements of the protocol~* Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in this protocol

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 12 adults with prior BCG
- 2 (Type: EXPERIMENTAL): 12 adults without prior BCG
- 3 (Type: EXPERIMENTAL): 12 Adolescents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete